352 material Form 8-K filings that 310 companies we cover made with the SEC in August 2024, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
WisdomTree announced a private offering of $300 million of convertible senior notes due 2029, subject to market conditions. Proceeds are intended in part to repurchase about $104 million of its 5.75% convertible notes due 2028 and to help fund a roughly $144 million cash repurchase of its Series A Preferred Stock from ETFS Capital Limited. The preferred repurchase depends on the offering closing and the 2028 note repurchases, so the outcome and final terms are not yet set.
Offering of $300 million convertible senior notes due 2029 to qualified institutional buyers, with an option for up to $45 million more; interest rate and conversion terms to be set at pricing
About $104 million of 5.75% convertible senior notes due 2028 targeted for repurchase; amounts depend on negotiations with holders
All 14,750 Series A Preferred shares, convertible into 14.75 million common shares, to be repurchased for approximately $144 million in cash, with the price based on the average stock price over four trading days
Related Investor Rights Agreement with ETFS Capital Limited to terminate at the repurchase closing
Metallus reported second-quarter 2024 net sales of $294.7 million and net income of $4.6 million, or $0.10 per diluted share, down from $356.6 million and $28.9 million a year earlier. The company expects adjusted EBITDA to decline sequentially in the third quarter of 2024 on weaker market demand, which points to continued pressure on shareholder earnings.
Net sales were $294.7 million, down 17 percent from $356.6 million in the second quarter of 2023 and down 8 percent from $321.6 million in the first quarter of 2024.
Adjusted EBITDA was $19.9 million, compared with $50.5 million in the second quarter of 2023 and $43.4 million in the first quarter of 2024.
Third-quarter 2024 adjusted EBITDA is expected to decline sequentially, and third-quarter shipments are expected to be lower than the second quarter.
Planned 2024 capital expenditures were reduced to approximately $55 million, a $5 million reduction from previous guidance.
DXC Technology reported first-quarter fiscal 2025 results for the quarter ended June 30, 2024, with total revenue down 6% year-over-year to $3.24 billion and GAAP diluted EPS down 18% to $0.14. The company raised parts of its full-year fiscal 2025 outlook, including non-GAAP diluted EPS and free cash flow, which may matter to shareholders even as reported revenue and GAAP earnings declined.
Net income was $25 million, down 40% year-over-year; non-GAAP diluted EPS was $0.74, up 17%.
Operating cash flow was $238 million, up 87%; free cash flow was $45 million.
Full-year non-GAAP diluted EPS outlook is now $2.75 to $3.00, up from $2.50 to $3.00 at the low end.
Full-year free cash flow outlook was raised to approximately $450 million from approximately $400 million.
QuinStreet reported fiscal fourth-quarter revenue of $198.3 million, up 52% year-over-year, and a GAAP net loss of $2.2 million, or $0.04 per share, compared with a loss of $55.9 million a year earlier. The company also gave initial fiscal 2025 guidance of $800 million to $850 million in revenue and $50 million to $60 million in adjusted EBITDA, which shareholders will watch against future results.
Q4 revenue was $198.3 million, up 52% year-over-year; Auto Insurance revenue grew over 200%.
Q4 GAAP net loss was $2.2 million ($0.04 per diluted share); adjusted net income was $6.5 million ($0.11 per diluted share).
Full fiscal 2024 revenue was $613.5 million, up 6%, with a GAAP net loss of $31.3 million ($0.57 per share).
Guidance: September quarter revenue of $220 million to $230 million and adjusted EBITDA of $14 million to $16 million; fiscal 2025 revenue of $800 million to $850 million and adjusted EBITDA of $50 million to $60 million.
ADMA Biologics reported second quarter 2024 total revenue of $107.2 million, up 78% from $60.1 million a year earlier, and GAAP net income of $32.1 million, compared with a net loss of $6.4 million in the second quarter of 2023. The company raised its full-year 2024 revenue guidance to more than $400 million from more than $355 million and its net income guidance to more than $105 million from $85 million. Revenue included a non-recurring $12.6 million increase tied to a change in estimate for U.S. Medicaid rebates.
Q2 2024 revenue of $107.2 million, up $47.1 million (about 78%) year over year, with the increase primarily from higher ASCENIV sales
Q2 2024 GAAP net income of $32.1 million, or $0.13 per diluted share, versus a net loss of $6.4 million in Q2 2023
FY 2024 revenue guidance raised to more than $400 million from more than $355 million; net income guidance raised to more than $105 million from $85 million
Corporate gross margin of 53.6% in Q2 2024, compared with 27.8% in Q2 2023; cash and cash equivalents of $88.2 million at June 30, 2024
Life360 reported unaudited Q2 2024 revenue of $84.9 million, up 20% year over year, and a net loss of $(11.0) million, compared with $(4.4) million a year earlier. The loss includes $5.8 million in IPO-related transaction costs. The company raised its full-year 2024 revenue and Adjusted EBITDA guidance, which matters to shareholders because it signals higher expected revenue and profit, though GAAP results were weaker than the prior year.
Q2 2024 total revenue was $84.9 million, up 20% year over year; net loss was $(11.0) million versus $(4.4) million in Q2 2023, including $5.8 million in IPO-related transaction costs.
Adjusted EBITDA was $11.0 million in Q2 2024, compared with $5.7 million in Q2 2023.
2024 consolidated revenue guidance was raised to $370 million-$378 million from $365 million-$370 million; Adjusted EBITDA guidance was raised to $36 million-$41 million from $30 million-$35 million.
Global monthly active users reached approximately 70.6 million, up 31% year over year, and Paying Circles reached 2.0 million.
DigitalOcean reported second-quarter 2024 revenue of $192 million, up 13% year over year, and GAAP net income of $19 million, compared with $665,000 a year earlier. The company also updated its full-year 2024 revenue guidance to $770 million to $775 million and gave third-quarter revenue guidance of $196 million to $197 million.
Q2 2024 revenue of $192 million, up 13% year over year; diluted EPS of $0.20 versus $0.01 a year earlier
Full-year 2024 total revenue guidance updated to $770 million to $775 million
Third-quarter 2024 total revenue guidance of $196 million to $197 million
Adjusted free cash flow was $37 million, down from $45 million in Q2 2023
Alarm.com reported second-quarter 2024 results on August 8, 2024, with total revenue up 4.4% to $233.8 million and GAAP net income attributable to common stockholders up 112.1% to $33.5 million, or $0.62 per diluted share. The company raised its full-year 2024 guidance for total revenue, non-GAAP adjusted EBITDA and non-GAAP adjusted net income attributable to common stockholders, which points to higher expected results for shareholders.
Total revenue rose 4.4% to $233.8 million; SaaS and license revenue rose 11.0% to $155.9 million.
GAAP net income attributable to common stockholders rose to $33.5 million, or $0.62 per diluted share, from $15.8 million, or $0.30, a year earlier.
Full-year 2024 total revenue guidance is $920.8 million to $931.2 million; non-GAAP adjusted EBITDA guidance is $165.0 million to $167.0 million.
Third-quarter 2024 SaaS and license revenue is expected to be $157.3 million to $157.5 million.
e.l.f. Beauty reported results for the three months ended June 30, 2024, with net sales up 50% to $324.5 million, but GAAP net income fell to $47.6 million from $53.0 million and GAAP diluted earnings per share fell to $0.81 from $0.93. The company raised its fiscal 2025 net sales and adjusted EPS outlook, which may matter to shareholders because the higher sales forecast is offset by lower GAAP profit in the quarter.
Net sales rose 50% to $324.5 million; adjusted diluted EPS was $1.10, unchanged from the prior-year quarter.
GAAP diluted EPS was $0.81 versus $0.93; SG&A rose to $180.6 million, or 56% of net sales.
Cash and cash equivalents were $109.0 million at June 30, 2024; long-term debt and finance lease obligations were $159.2 million.
Artivion reported second-quarter 2024 revenue of $98.0 million, up 10% from $89.3 million a year earlier, and a net loss of $2.1 million ($0.05 per diluted share), narrower than the $3.4 million loss ($0.08 per share) in the prior-year quarter. The company raised its full-year 2024 revenue and adjusted EBITDA guidance, though the increases at the midpoint are small.
Q2 2024 revenue $98.0 million vs. $89.3 million in Q2 2023, up 10% on both GAAP and constant currency bases
Q2 2024 net loss of $2.1 million ($0.05 per diluted share) vs. net loss of $3.4 million ($0.08 per share) in Q2 2023; non-GAAP net income $2.9 million ($0.07 per share)
Adjusted EBITDA rose 35% to $18.6 million from $13.8 million
FY24 revenue guidance raised to $388 million to $396 million from $386 million to $396 million; adjusted EBITDA guidance raised to $69 million to $72 million from $68 million to $72 million
CarGurus reported second quarter 2024 results with total revenue of $218.7 million, down 9% from a year earlier, and a GAAP net loss of $68.7 million, compared with net income of $13.8 million in the same period of 2023. Marketplace revenue rose 14% to $195.2 million, while the net loss reflects a $127.7 million goodwill and long-lived asset impairment. The company also gave third quarter 2024 guidance for total revenue of $212 million to $232 million.
Q2 2024 total revenue was $218.7 million, down 9% year over year; Marketplace revenue rose 14% to $195.2 million.
GAAP net loss was $68.7 million, or $0.66 per diluted share, versus net income of $13.8 million in Q2 2023; the loss includes $127.7 million in impairment charges.
Non-GAAP Consolidated Adjusted EBITDA was $55.6 million, up 23% year over year, with a 25% margin.
Third quarter 2024 guidance: total revenue of $212 million to $232 million, Non-GAAP EPS of $0.38 to $0.44.
Expedia Group reported second quarter 2024 revenue of $3.6 billion, up 6% from a year earlier, and diluted EPS of $2.80 versus $2.54. CEO Ariane Gorin said July brought a more challenging macro environment and softer travel demand, and the company is adjusting its expectations for the rest of the year.
Q2 2024 gross bookings were $28.8 billion, up 6%, and revenue was $3.6 billion, up 6%.
Diluted EPS was $2.80 versus $2.54; adjusted EPS was $3.51 versus $2.89, up 21%.
Net income attributable to Expedia Group was $386 million, roughly flat with $385 million a year earlier.
Management said it has seen a softening in travel demand in July and is adjusting expectations for the rest of 2024.
Tennant Company reported second-quarter 2024 net sales of $331.0 million, up 2.9% from a year earlier, while net income fell 10.9% to $27.9 million and diluted EPS fell to $1.45 from $1.68. The company raised its full-year 2024 guidance, with net sales now expected at $1,280 million to $1,305 million and Adjusted EBITDA at $205 million to $215 million.
Q2 2024 net sales were $331.0 million, up 2.9%, or 2.7% organic; Asia Pacific sales fell 13.5%.
Net income was $27.9 million versus $31.3 million, and diluted EPS was $1.45 versus $1.68; the company cited ERP modernization and transaction and integration costs.
Adjusted diluted EPS was $1.83 versus $1.86 a year earlier, and Adjusted EBITDA was $58.6 million, up 1.7%.
Updated 2024 guidance: net sales $1,280 million to $1,305 million (previously $1,270 million to $1,295 million); Adjusted EBITDA $205 million to $215 million (previously $198 million to $213 million).
Medical Properties Trust reported a second-quarter 2024 net loss of $321 million, or $0.54 per share, compared with a net loss of $42 million, or $0.07 per share, a year earlier. Normalized FFO fell to $139 million, or $0.23 per share, from $285 million, or $0.48 per share. The company also amended its credit agreement, which cuts the revolver to $1.28 billion and limits cash dividends to $0.08 per share per quarter through September 30, 2025.
Q2 net loss of $321 million ($0.54 per share) versus $42 million ($0.07 per share) a year earlier, including about $400 million in real estate gains and about $700 million in impairments and negative fair value adjustments
Normalized FFO of $139 million ($0.23 per share) versus $285 million ($0.48 per share) in the year-earlier quarter
Credit amendment dated August 6, 2024 cuts revolving commitments from $1.4 billion to $1.28 billion and limits cash dividends to $0.08 per share per quarter through September 30, 2025
Maximum total leverage ratio raised from 60% to 65%; minimum unsecured interest coverage ratio lowered from 1.75:1.00 to 1.45:1.00; borrowing spreads rise to 300 basis points during the covenant period
Curtiss-Wright reported second quarter 2024 sales of $785 million, up 11% from the prior year, and reported diluted EPS of $2.58. The company raised its full-year 2024 adjusted guidance for sales, operating income, diluted EPS and free cash flow, citing strong first-half results and its outlook for the rest of the year.
Q2 2024 adjusted diluted EPS was $2.67, up 24%; reported diluted EPS was $2.58.
Full-year 2024 adjusted diluted EPS guidance was raised to $10.40 to $10.65, from $10.10 to $10.40.
Full-year 2024 adjusted sales growth guidance was raised to 6% to 8%, from 5% to 7%.
Restructuring actions are expected to cost about $15 million in 2024.
Warby Parker reported second-quarter 2024 net revenue of $188.2 million, up 13.3% from the prior year, and a GAAP net loss of $6.8 million, down from $15.9 million a year earlier. The company raised its full-year 2024 net revenue guidance to $757 million to $762 million, which matters to shareholders because it signals faster expected growth while the company still reports a GAAP net loss.
Q2 net revenue of $188.2 million, up 13.3% from $166.1 million in the prior year period
GAAP net loss of $6.8 million, compared with $15.9 million in the prior year period
Full-year 2024 net revenue guidance raised to $757 million to $762 million, growth of about 13% to 14%
Adjusted EBITDA of $19.6 million, with Adjusted EBITDA Margin of 10.4%
First Advantage reported second-quarter 2024 revenue of $184.5 million, down 0.4% from a year earlier, and net income of $1.9 million, down 81%, which includes $9.2 million of expenses tied to the pending Sterling Check Corp. acquisition. The company reaffirmed its full-year 2024 guidance, while CFO David Gamsey announced his retirement and Chief Accounting Officer Steven Marks was named his successor effective November 8, 2024.
Q2 2024 revenue was $184.5 million, versus $185.3 million in Q2 2023; adjusted EBITDA was $55.8 million, flat year over year.
Net income was $1.9 million, or $0.01 per diluted share, versus $9.8 million, or $0.07 per share, a year earlier.
Adjusted diluted EPS was $0.21, versus $0.24 in the prior-year quarter.
Full-year 2024 guidance was reaffirmed: revenue of $750 million to $800 million and adjusted EBITDA of $228 million to $248 million.
YETI reported second-quarter 2024 net sales up 15% to $463.5 million, or 9% on an adjusted basis that excludes a 2023 recall reserve adjustment, and GAAP diluted EPS of $0.59, up from $0.44. The company raised its fiscal 2024 adjusted sales growth outlook to 8% to 10% and its adjusted EPS outlook to $2.61 to $2.65, which matters to shareholders because it signals higher expected profit for the year.
Net sales rose 15% to $463.5 million; adjusted net sales rose 9% after excluding the $24.5 million unfavorable recall reserve impact in the prior-year quarter.
GAAP diluted EPS was $0.59 versus $0.44; adjusted EPS was $0.70 versus $0.57.
Fiscal 2024 adjusted EPS outlook raised to $2.61 to $2.65, from $2.49 to $2.62 previously.
Cash was $212.9 million at June 29, 2024, and $200 million remained under the share repurchase program.
Privia Health reported second-quarter 2024 results on August 8, 2024, with total revenue of $422.3 million, up 2.2% from a year earlier, while net income attributable to the company fell to $3.5 million from $7.3 million and diluted EPS fell to $0.03 from $0.06. The company also raised its full-year 2024 guidance to the mid-to-high end of its ranges for all metrics, including GAAP revenue of $1,600 million to $1,675 million, so shareholders get higher revenue expectations alongside lower GAAP earnings this quarter.
Q2 2024 total revenue $422.3 million, up 2.2% from $413.4 million; operating income $5.1 million, down 27.0%
Net income attributable to Privia Health $3.5 million, or $0.03 per share, versus $7.3 million, or $0.06, a year earlier
Adjusted EBITDA $22.0 million, up 14.0%; cash and cash equivalents $387.4 million and no debt as of the quarter
FY 2024 guidance raised to mid-to-high end; GAAP revenue guidance $1,600 million to $1,675 million, Adjusted EBITDA $85 million to $90 million
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.